[Controlled study of the effect of Stressen on homocysteine blood levels in patients with vascular disease].
OBJECTIVE
Plasma levels of folate and vitamin B12 are inversely related to homocysteinemia and nowadays a further supplement of these vitamins, other than diet, is considered useful for lowering homocysteine blood levels. Stressen possesses the requirements for the control of this biochemical parameter; this study had the purpose to verify the activity of the product in patients affected by vascular disease.


METHODS
40 patients have taken a bottle of Stressen twice daily for 30 days and 20 subjects, suffering from the same pathology and non treated with the drug, have been considered as controls. Homocysteinemia was evaluated at the beginning and at the end of the treatment.


RESULTS
Stressen determined a statistical reduction of 51.1% of basal concentration (p<0.0001), while levels of controls remained unchanged after the 30 days period.


CONCLUSIONS
Supplement of vitamin B12 and folate, consisting in Stressen administration, normalized homocysteinemia. Furthermore, arginine glutamate, in the composition of the product, represents substrate for NO synthase and could be particularly useful for the treatment of vascular disease, improving endothelial-dependent dilation.
Monteleone
F
F
Azienda Ospedaliera di Sciacca, Servizio di Angiologia, Sciacca (AG), Italia. francomonteleone@supereva.it
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D003038:Cobamides / Q000008:administration & dosage / Q000627:therapeutic use*; D004151:Dipeptides / Q000008:administration & dosage / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D004338:Drug Combinations; D004730:Endothelium, Vascular / Q000187:drug effects; D005260:Female; D006710:Homocysteine / Q000097:blood*; D006801:Humans; D020138:Hyperhomocysteinemia / Q000097:blood / Q000150:complications* / Q000188:drug therapy*; D007124:Immunoenzyme Techniques; D002955:Leucovorin / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D019001:Nitric Oxide Synthase / Q000378:metabolism; D016896:Treatment Outcome; D014652:Vascular Diseases / Q000097:blood / Q000150:complications*; D014664:Vasodilation / Q000187:drug effects
D003038:Cobamides; D004151:Dipeptides; D004338:Drug Combinations; D006710:Homocysteine; D019001:Nitric Oxide Synthase; C000913:cobamamide; D002955:Leucovorin; C024362:arginine glutamate